RxDoctor Payments Data

Martha Narasimhan-Narayanan

Family · la Jolla, CANPI 1114652229

Payments from drug & device makers

$3,261in general payments, 2019–2025

Across 59 payments — averaging $55.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$371
  • Novo Nordisk$348
  • AstraZeneca$342
  • Regeneron Healthcare Solutions, Inc.$222
  • Gilead$220
  • Exact Sciences$152
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,261 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$48,875
OzempicSemaglutide22$23,620
EliquisApixaban11$14,087
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$13,312
Ezetimibe33$2,004
Celecoxib11$434
Rosuvastatin Calcium35$425
Pantoprazole Sodium22$335
Omeprazole16$308
Metformin Hcl ErMetformin Hcl18$308
Amlodipine Besylate40$305
Ramipril19$290
Escitalopram Oxalate14$260
Losartan Potassium16$255
Gabapentin18$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$112$48,87550 claims
Novo NordiskOzempic$348$23,62022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →